Codexis is a producer of cellulase and other enzymes used for the production of biofuels, detergent alcohols, and pharmaceutical ingredients. It's share price has fallen by 86% since its 2010 IPO and recently set a new low. The end of a R&D agreement with Shell, the possible end to an important licensing agreement with Dyadic, and faltering cellulosic ethanol production in the U.S. all raise serious concerns regarding the company's future growth prospects that investors should not overlook.
When I first began working in the biofuels sector back in 2008, a small company called Codexis (NASDAQ:CDXS) was attracting quite a bit of attention. The company was (and still is) a leading developer of a genetically-engineered enzyme...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|